Mantle cell lymphoma refractory
Information
- Disease name
- Mantle cell lymphoma refractory
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01389427 | Completed | Phase 1/Phase 2 | Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). | November 2011 | September 2015 |
| NCT05645744 | Enrolling by invitation | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. | September 29, 2021 | July 2041 | |
| NCT05360238 | Recruiting | Phase 1/Phase 2 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | May 24, 2022 | September 2026 |
| NCT05833763 | Recruiting | Phase 2 | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. | October 12, 2023 | April 2037 |
| NCT05864742 | Recruiting | Phase 2 | Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma | September 7, 2023 | June 1, 2029 |